| abstract |
the pharmaceutical composition for the treatment of disorders related to phosphodiesterase comprises administering to the individual a therapeutically effective amount of a compound of formula i, or compounds selected from the group consisting of niclosamide, oxyclozanide, rafoxanide, closantel, dibromsalan, metabromsalan, tribromsalan and nitazoxanide , and prodrugs, metabolites, or salts, solvates and their pharmaceutically acceptable polymorphs, in a pharmaceutically acceptable excipient, vehicle or diluents. |